Mulders-Manders, Catharina M. http://orcid.org/0000-0002-8235-2629
Kanters, Tim A.
van Daele, Paul L. A.
Hoppenreijs, Esther
Legger, G. Elizabeth
van Laar, Jan A. M.
Simon, Anna
Hakkaart-van Roijen, Leona
Funding for this research was provided by:
ZonMw (152001023)
Article History
Received: 21 November 2017
Accepted: 4 April 2018
First Online: 20 April 2018
Ethics approval and consent to participate
: This study was assessed by the local medical ethics committees of the Radboudumc (registration number 2015–1643), Erasmus MC (registration number 2015–501), and university medical center Groningen (registration number 2015/166) and according to Dutch law was exempt from approval by all three, because of its retrospective and observational design and the anonymous storage of patient data.
: All patients or their parents gave written informed consent for participation in the study and publication of the study’s results.
: TK, LHvR and JvL provided consulting services for Novartis, the manufacturer of canakinumab. AS has received funding from Novartis for other research, in which CM participated as a consultant. AS has provided consulting services for SOBI-Biovitrum, the manufacturer of anakinra, in the past. Neither Novartis, nor SOBI-Biovitrum were involved in the design of this study, the data collection or analysis, or the writing of the manuscript.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.